Cwm LLC Has $112,000 Stock Holdings in argenex SE $ARGX

Cwm LLC reduced its stake in argenex SE (NASDAQ:ARGX) by 10.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 203 shares of the company’s stock after selling 24 shares during the quarter. Cwm LLC’s holdings in argenex were worth $112,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ARGX. Millennium Management LLC raised its holdings in argenex by 316.9% in the 1st quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock valued at $158,977,000 after acquiring an additional 204,180 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of argenex by 1,203.4% during the first quarter. BNP Paribas Financial Markets now owns 133,359 shares of the company’s stock worth $78,931,000 after buying an additional 123,127 shares in the last quarter. Braidwell LP lifted its holdings in shares of argenex by 99.2% during the first quarter. Braidwell LP now owns 160,849 shares of the company’s stock worth $95,201,000 after buying an additional 80,083 shares in the last quarter. Lord Abbett & CO. LLC lifted its holdings in shares of argenex by 33.2% during the first quarter. Lord Abbett & CO. LLC now owns 274,700 shares of the company’s stock worth $162,585,000 after buying an additional 68,498 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in shares of argenex by 54.4% during the first quarter. Adage Capital Partners GP L.L.C. now owns 138,637 shares of the company’s stock worth $82,054,000 after buying an additional 48,850 shares in the last quarter. 60.32% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ARGX has been the subject of a number of research reports. Piper Sandler lifted their target price on argenex from $750.00 to $820.00 and gave the stock an “overweight” rating in a report on Tuesday, August 26th. Wells Fargo & Company boosted their price target on argenex from $741.00 to $756.00 and gave the company an “overweight” rating in a research note on Thursday, July 31st. Morgan Stanley increased their price target on shares of argenex from $766.00 to $1,040.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 1st. Guggenheim reiterated a “buy” rating and set a $1,070.00 price target on shares of argenex in a research report on Thursday, September 18th. Finally, JPMorgan Chase & Co. increased their price target on shares of argenex from $775.00 to $830.00 and gave the stock an “overweight” rating in a research report on Monday, August 4th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $851.70.

argenex Stock Performance

NASDAQ:ARGX opened at $818.50 on Friday. The company has a market capitalization of $50.40 billion, a PE ratio of 35.14, a P/E/G ratio of 0.89 and a beta of 0.46. The company has a 50 day simple moving average of $769.14 and a two-hundred day simple moving average of $654.03. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $855.46.

argenex (NASDAQ:ARGX) last released its earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.90. The business had revenue of $866.79 million during the quarter, compared to the consensus estimate of $776.82 million. argenex had a net margin of 41.58% and a return on equity of 22.33%. Research analysts predict that argenex SE will post 3.13 EPS for the current year.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.